A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

Sex: All

Ages: 18 Years – 60 Years

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 240

Sponsor: Bristol-Myers Squibb

Summary

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.

Eligibility Criteria

Inclusion Criteria * Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive * Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments * Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment * Other protocol-defined Inclusion/Exclusion criteria apply

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07226817). StuddyBuddy aggregates publicly available trial information.